From what 4 stock analysts predict, the share price for Repligen Corp (RGEN) might decrease by 8.84% in the next year. This is based on a 12-month average estimation for RGEN. Price targets go from $175.00 to $210.00. The majority of stock analysts believe RGEN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
RGEN is a stock in Health Care which has been forecasted to be worth $190.00 as an average. On the higher end, the forecast price is $210.00 USD by rachel vatnsdal from J.P. Morgan and on the lower end RGEN is forecasted to be $175.00 by timothy daley from Wells Fargo.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
matt hewitt Craig-Hallum | Buy | None | rated | Feb 16, 2024 |
paul knight KeyBanc | Buy | $220.0 | maintained | Feb 15, 2024 |
conor mcnamara RBC Capital | Buy | $200.0 | maintained | Jan 24, 2024 |
rachel vatnsdal J.P. Morgan | Buy | $210.0 | maintained | Dec 20, 2023 |
justin bowers Deutsche Bank | Hold | $175.0 | maintained | Dec 18, 2023 |
puneet souda Leerink Partners | Buy | $175.0 | maintained | Dec 7, 2023 |
robert wasserman Benchmark Co. | Hold | None | downgraded | Dec 4, 2023 |
timothy daley Wells Fargo | Buy | $175.0 | maintained | Nov 6, 2023 |
daniel arias Stifel Nicolaus | Buy | $165.0 | maintained | Nov 2, 2023 |
alexander nowak Craig-Hallum | Buy | None | rated | Oct 2, 2023 |
jacob johnson Stephens | Buy | $200.0 | maintained | Aug 3, 2023 |
julia qin J.P. Morgan | Buy | $220.0 | maintained | May 2, 2023 |
brandon couillard Jefferies | Hold | $170.0 | maintained | Apr 28, 2022 |
hugo solvet BNP Paribas | Buy | $330.0 | initiatedcoverage | Oct 14, 2021 |
ram selvaraju H.C. Wainwright | Buy | $240.0 | reiterated | Jun 22, 2021 |
tycho peterson J.P. Morgan | Buy | $215.0 | maintained | Nov 5, 2020 |
joseph munda First Analysis | Buy | $110.0 | upgraded | Nov 1, 2019 |
tracy marshbanks First Analysis | Buy | $110.0 | upgraded | Nov 1, 2019 |
david westenberg Piper Sandler | Buy | $65.0 | upgraded | Dec 17, 2018 |
drew jones Stephens | Buy | $65.0 | reiterated | Nov 2, 2018 |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
When did it IPO
1986
Staff Count
2,025
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Anthony J. Hunt
Market Cap
$11.64B
In 2023, RGEN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that RGEN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
ARCC-USD
$20.11
MORN-USD
$273.91
EVRG-USD
$50.61
GTLB-USD
$70.18
MSTR-USD
$699.56
EXAS-USD
$63.29